Japanese Regulators Approve Merck KGaA MET Inhibitor With ArcherDx CDx

The US Food and Drug Administration on Friday warned consumers to watch out for companies marketing unproven products for diagnosing, preventing, or treating COVID-19.

While many in the US and Europe have only recently come to understand the scope and severity of the SARS-CoV-2 pandemic, a handful of proteomics labs have been studying the virus since the beginning of the year.

A new UK-based research consortium is betting that sequencing the virus that causes COVID-19 can provide policymakers with a clearer picture of the spread of the epidemic across the country as diagnostic testing remains limited.

In a new study published in Nature on Wednesday, researchers in China described the cell type composition of all major human organs, based on the RNA sequences of more than 500,000 single cells from Chinese Han donors.

Personalis reported after the close of the market on Wednesday that its fourth quarter revenues rose 38 percent year over year

Oncocyte said after the close of the market on Wednesday that its fourth quarter net loss rose 77 percent year over year as it pushed toward a transition to commercial test operations.

Biocept said after the close of the market on Wednesday that its fourth quarter revenues more than doubled year over year, driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimbursement per patient.

HTG Molecular Diagnostics reported after the close of the market on Wednesday an 11 percent year-over-year drop in its full-year revenues, driven by a significant decrease in collaboration revenue.

Quidel said after the close of the market on Wednesday that it has received expanded Emergency Use Authorization from the US Food and Drug Administration for the Lyra SARS-CoV-2 assay.

The Association of the British Pharmaceutical Industry (ABPI) has issued a statement.

Swift Biosciences has partnered with LGC Biosearch Technologies to incorporate Swift's targeted sequencing technology into LGC's kits and service offerings for the worldwide ag-bio market.

Natera reported after the close of the market on Wednesday that its fourth quarter 2019 revenues grew 24 percent year over year.

Swift Biosciences has partnered with LGC Biosearch Technologies to incorporate Swift's targeted sequencing technology into LGC's kits and service offerings for the worldwide ag-bio market.

Illumina has asked a US Court for a preliminary injunction to prevent BGI from distributing sequencers in the US to a handful of labs on a no-cost trial basis.